GSK plc (GSK) Gets FDA Approval for Hibsago in CHB

GSK's bepirovirsen (HIBSAGO) received FDA approval for chronic hepatitis B (CHB) treatment, showing 19% functional cure rates in trials. The six-month treatment can be administered at home after the first dose. GSK licensed the drug from Ionis in 2019, with Ionis eligible for milestone payments and royalties. CHB affects approximately 1.7 million people in the U.S.

Hutchmed (00013.HK) finalized a licensing deal with GSK for its KRAS-EGFR conjugate therapy, HMPL-A830. GSK gains global rights (excluding Greater China) for $110M upfront, with up to $1.185B in milestones. Hutchmed leads Phase I trials, while GSK handles later stages. The drug targets cancers with KRAS mutations, currently in early clinical testing.

GSK's depemokimab (Exdensur) showed significant improvements in asthma patients' quality of life, with benefits seen as early as 4 weeks and persisting through 52 weeks, according to a study presented at the CHEST Annual Meeting. The treatment was administered subcutaneously twice a year, with 363 patients receiving 100 mg doses and 196 on placebo. Mean changes in symptom, activity, and impact scores on the St.

GSK (NYSE: GSK) received FDA approval for Hibsago, a treatment for chronic hepatitis B. The company offers a 3.49% dividend yield with a 39% payout ratio and a 2.5% 3-year dividend growth rate. GSK's stock is trading at $50.63, 9.8% above its GF Value of $46.13. The company has a GF Score of 77/100, indicating solid financial health and valuation.

GSK's drug Hibsago (bepirovirsen) received approval for chronic hepatitis B treatment, showing 19% of trial participants had no detectable virus 24 weeks post-treatment. The six-month course offers potential functional cure and self-administration options. GSK licensed the drug from Ionis, with regulatory decisions pending in other regions.

GSK PLC announced FDA approval of Hibsago (generic name bepirovirsen) for chronic hepatitis B treatment. The drug, a first-in-class antisense oligonucleotide, showed 19% functional cure rates in trials. GSK shares closed up 0.7% at 1,868.50 pence in London. The approval was granted under priority review and breakthrough therapy designation, according to the company.